Mukul Agrawal gains Rs 98,44,80,000 & Vijay Kedia gains Rs 31,99,56,000 from this multibagger pharma stock; Hit 20% upper circuit on July 14

On Monday, one of the Top Gainers on BSE & NSE, shares of this multibagger pharma company hit a 20 per cent to Rs 14,767.20 per share from its previous closing of Rs 12,306 per share. The stock’s 52-week high is Rs 18,089.55 per share while its 52-week low is Rs 7,900 per share. The shares of the company saw a spurt in volume by more than 63 times.

Two ace investors, Vijay Kedia and Mukul Agrawal, own 1.01 per cent (1,30,000 shares) and 3.12 per cent (4,00,000 shares) stake in the company, respectively, as of March 2025. Therefore, at day’s high, Mukul Agrawal gained Rs 98,44,80,000 and Vijay Kedia gained Rs 31,99,56,000 (at intraday high price).

The stock name is Neuland Laboratories Ltd.

About the Company

Neuland Labs, a pioneer in API manufacturing, has been serving customers in nearly 80 countries for over four decades. With a strong focus on quality and compliance, they have developed and manufactured over 300 processes and 100 APIs. Their commitment to regulatory excellence is evident in their 978+ regulatory filings across major markets like the US, EU, and others. Their manufacturing facilities, inspected and approved by leading regulatory agencies such as the US FDA, adhere to stringent cGMP standards, ensuring product quality and safety. This robust track record, backed by certifications from various regulatory bodies worldwide, solidifies Neuland Labs' position as a trusted partner in the pharmaceutical industry.

The company has a market cap of over Rs 18,000 crore with a PE of 74x, an ROE of 15 per cent and an ROCE of 19 per cent. The stock gave multibagger returns of 395 per cent in 2 years, 1,035 per cent in 3 years and a whopping 2,200 per cent in 5 years.

Do you own shares of Neuland Laboratories Ltd in your portfolio? Do let us know in the comments below

Disclaimer: The article is for informational purposes only and not investment advice.